Using Nicotinamide-Riboside and Pterostilbene to treat osteoarthritis
Official title: Development of Nicotinamide-Riboside plus Pterostilbene as a Disease Modifying Osteoarthritis Therapeutic
Funded at Elysium Health, INC. · NIH-10699600 · Data updated 2026-11-12
This study is looking at a new way to help people with osteoarthritis by using a combination of two compounds that might slow down or even improve the condition, aiming to make your joints feel better and work more effectively.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Elysium Health, INC. NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | June 1, 2023 |
| Project end | May 31, 2026 |
| Funding year | 2023 |
| Award (this year) | $283,071 |
| NIH project number | 1R41AR082748-01 |
| Project ID | NIH-10699600 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with osteoarthritis, particularly those over the age of 65 who are experiencing joint pain and disability.
✕Less likely to help
Patients with osteoarthritis who are not responsive to new therapeutic approaches or those with advanced joint degeneration may not benefit from this research.
What this research studies
This research investigates a new treatment approach for osteoarthritis (OA) by combining two compounds, Nicotinamide-Riboside and Pterostilbene, which may help slow or reverse the progression of the disease. Osteoarthritis is a common joint condition that causes pain and disability, particularly in older adults. The study aims to enhance cellular function and reduce inflammation in the joints by increasing levels of NAD+, a vital molecule for cellular health. By focusing on the underlying mechanisms of OA, this research seeks to develop a therapy that modifies the disease rather than just alleviating symptoms.
Why it matters
Potential benefit: If successful, this research could provide a new disease-modifying treatment for osteoarthritis, improving quality of life for millions of patients.
How similar studies have gone: While the approach of using NAD+ precursors and sirtuin activators is promising, it is still relatively novel and has not been extensively tested in the context of osteoarthritis.
Where this research is happening
-
Elysium Health, INC.
New York, United States Active
Researchers
- Principal investigator: Dellinger, Ryan William — Elysium Health, INC.
- Study coordinator: Dellinger, Ryan William
Related research
Other NIH-funded projects on the same topics.
-
Understanding how knee pain and knee obesity and muscle loss affect knee osteoarthritis
This project looks at how knee swelling, excess knee fat, and muscle loss relate to pain and structural changes in knee osteoarthritis in adults.
-
Identifying OA subtypes and early warning signs before joint damage
This grant asks researchers to find early, invisible clues of osteoarthritis subtypes so we can target treatments before joints are damaged.
-
Digital biomarkers to guide personalized rehab after ACL injury
Aims to use wearable sensors and phone videos to predict early osteoarthritis risk after ACL surgery so rehabilitation can be tailored to each patient.
-
Aberrant mechano-oxygen coupling linked to zinc-rich mineralization in osteoarthritis
Aims to understand how abnormal joint forces affect cartilage and bone, causing zinc-rich mineral deposits and harmful blood vessel growth in osteoarthritis.
-
Notch signaling in TMJ osteoarthritis: uncovering mechanisms and new targets
Researchers are studying how Notch signaling affects TMJ osteoarthritis to identify new ways to protect and repair the jaw joint.
-
Nanoparticles delivering an sPLA2 blocker for knee osteoarthritis
This project uses tiny, drug-filled nanoparticles to deliver an sPLA2-blocking medicine into the knee to reduce inflammation and slow knee osteoarthritis in people with painful knee OA.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.